Abrogation of Immunogenic Properties of Gliadin Peptides through

Subscriber access provided by Warwick University Library

Article

Abrogation of immunogenic properties of gliadin peptides through transamidation by microbial transglutaminase is acyl-acceptor dependent Lin Zhou, Yvonne M.C. Kooy-Winkelaar, Robert A. Cordfunke, Irina Dragan, Allan Thompson, Jan Wouter Drijfhout, Peter A. van Veelen, Hongbing Chen, and Frits Koning J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.7b02557 • Publication Date (Web): 03 Aug 2017 Downloaded from http://pubs.acs.org on August 3, 2017

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 35

Journal of Agricultural and Food Chemistry

1

Abrogation of immunogenic properties of gliadin peptides through transamidation

2

by microbial transglutaminase is acyl-acceptor dependent

3 4

Lin Zhou 1, 2, 3, Yvonne M.C. Kooy-Winkelaar 3, Robert A. Cordfunke 3, Irina Dragan 4,

5

Allan Thompson 3, Jan Wouter Drijfhout 3, Peter A. van Veelen 4, Hongbing Chen 1*&

6

Frits Koning 3*

7

1

8

Nanchang 330047, China

9

2

College of Food Science, Nanchang University, Nanchang 330031, China

10

3

Department of Immunohematology and Blood Transfusion, Leiden University

11

Medical Center, Leiden 2333 ZA, The Netherlands

12

4

13

2333 ZA, The Netherlands

State Key Laboratory of Food Science and Technology, Nanchang University,

Center for Proteomics & Metabolomics, Leiden University Medical Center, Leiden

14 15

*Corresponding author

16

[email protected], Tel: +86 791 8833 4552

17

[email protected], Tel: +3171 526 6673

18 19 20 21 22 23 24

1 ACS Paragon Plus Environment


Page 2 of 35

25

ABSTRACT

26

Wheat gluten confers superior baking quality to wheat based products but elicits a pro-

27

inflammatory immune response in patients with celiac disease. Transamidation of

28

gluten by microbial transglutaminase (mTG) and tissue transglutaminase (tTG) reduces

29

the immunogenicity of gluten, however, little information is available on the minimal

30

modification sufficient to eliminate gliadin immunogenicity nor has the effectiveness of

31

transamidation been studied with T-cell clones from patients. Here we demonstrate that

32

mTG can efficiently couple three different acyl-acceptor molecules, L-lysine, glycine

33

ethyl ester and hydroxylamine, to gliadin peptides and protein. While all three acyl-

34

acceptor molecules were cross-linked to the same Q-residues, not all modifications were

35

equally effective in silencing T-cell reactivity. Finally, we observed that tTG can

36

partially reverse the mTG-catalyzed transamidation by its isopeptidase activity. These

37

results set the stage to determine the impact of these modifications on the baking quality

38

of gluten proteins and in vivo immunogenicity of such food products.

39 40

KEYWORDS: acyl-acceptor molecule, gliadin, immunogenic properties, microbial

41

transglutaminase, transamidation

42 43 44 45 46 47 48


Page 3 of 35


49

INTRODUCTION

50

Celiac disease (CD) is a T-cell-mediated autoimmune enteropathy, induced by the

51

ingestion of prolamins from wheat, rye or barley, with an estimated worldwide

52

prevalence of approximately 1%

1

53

approximately 95% of patients

carry HLA (human leukocyte antigen)-DQ2

54

(A1*0501/B1*0201), while the remainder is usually HLA-DQ8 (A1*0301/B1*0302)

55

positive 2. This association is explained by the observation that T-cell specific for gluten

56

peptides bound to either HLA-DQ2 or HLA-DQ8 are found in patients with CD 3, 4. At

57

present, there is no effective treatment for CD patients except a permanent life-long

58

gluten free diet (GFD).

59

A number of gluten T-cell epitopes associated with HLA-DQ receptors of CD have

60

been identified 5. A highly antigenic 33-mer peptide from α-gliadin is resistant to gastric

61

and intestinal proteolysis, and contains six partially overlapping T-cell epitopes:

62

PFPQPQLPY (DQ2.5-glia-α1a), PYPQPQLPY (DQ2.5-glia-α1b, two copies) and

63

PQPQLPYPQ (DQ2.5-glia-α2, three copies)

64

transglutaminase (tTG) plays a critical role in CD pathogenesis. Specifically, the tTG

65

mediated deamidation of Q→E strongly enhances the binding of gluten epitopes to

66

HLA-DQ2 or HLA-DQ8 and such peptide-HLA-DQ complexes strongly activate

67

gluten-specific T-cell clones 8-10.

68

Microbial transglutaminase (mTG) from Streptomyces mobaraensis is a food-grade

69

transamidase and widely used in the food industry. Similar to tTG, mTG can deamidate

70

glutamine residues to glutamic acid residues, resulting in gluten peptides with T-cell

71

stimulatory properties

72

specific antibodies 15. Here, the in vitro transamidation of Q by either tTG or mTG can

. CD has a strong genetic component as

6, 7

. It is well established that tissue

11-14

. In contrast mTG does not affect the reactivity of gliadin-



Page 4 of 35

73

prevent the deamidation process induced by tTG present in the human intestine. Indeed,

74

previous studies indicated that selective modification of glutamine residues present in

75

toxic epitopes by mTG transamidation using L-lysine or L-lysine methyl ester prevented

76

the deamidation process 16, 17. Moreover, Elli et al. found that the modification of gluten

77

by tTG with L-lysine inhibited the duodenal immunological effects on cultured biopsies

78

from CD patients

79

ester reduced the number of clinical relapses in challenged patients but did not eradicate

80

the antigenicity of gluten

81

less immunoreactive gluten

82

mTG to obtain wheat flour with decreased CD toxic epitopes

83

mTG has much lower deamidation activity as compared with tTG 22 and mTG is active

84

with a variety of acyl-acceptor molecules so that several additional acyl-acceptor

85

molecules can be used instead of lysine, and link them to peptides or proteins of interest

86

23, 24

87

Gluten has unique properties which make it highly suitable for the preparation of high

88

quality dough, which are tightly linked to its characteristic amino acid composition

89

dominated by high glutamine content. Therefore, modification of such glutamines by

90

transamidation could have negative consequences

91

desirable, however, little information on the minimal modification sufficient to

92

eliminate gluten immunogenicity is available. Therefore, we investigated whether apart

93

from lysine other acyl-acceptor molecules can also be used with mTG to eliminate the

94

T-cell stimulatory properties of gliadin peptides and proteins. For this purpose we

95

compared the effect of transamidation with L-lysine (Lys), glycine ethyl ester (GEE)

96

and hydroxylamine (HA) as acyl-acceptor molecules.

18

. Additionally, gluten transamidated by tTG and L-lysine methyl

19

. Transamidated gluten can be used to produce bread with 20

and recently, Ribeiro et al exploited n-butylamine and 21

. Most importantly,

.

25

. Minimal modification is thus


Page 5 of 35


97 98

MATERIALS AND METHODS

99

Synthetic peptides and chemicals

100

DQ2.5-glia-α1a

(native

form

LQPFPQPQLPYPQ

and

deamidated

form

101

LQPFPQPELPYAA), DQ2.5-glia-α2 (native form PFPQPQLPYPQPQ and deamidated

102

form AAPQPELPYPQPQ) and deamidated 33-mer (LQLQPF (PQPELPY)3 PQPQPF)

103

peptides were synthesized by standard Fmoc chemistry on a multiple peptide

104

synthesizer (Syroll, MultiSynTech GmbH, Witten, Germany). The native 33-mer

105

peptide (LQLQPF (PQPQLPY)3 PQPQPF) was synthesized by GL Biochem Ltd

106

(Shanghai, China). Details on the HLA-DQ2 binding properties of the gliadin peptides

107

can be found in reference Sollid et al 5. The purity and integrity of the peptides was

108

confirmed by reversed-phase high performance liquid chromatography (RP-HPLC) and

109

mass spectrometry. mTG from Streptomyces mobaraensis was donated by Jiangsu

110

Yiming Biological Products Co., Ltd. (Jiangsu, China) with a declared activity of 1,000

111

units (U)/ g and has an amino sequence that is identical to Ajinomoto transglutaminase.

112

L-lysine (Lys, >98%), was bought from Sangon Biotech (Shanghai, China). Glycine

113

ethyl ester hydrochloride (GEE, >98%), hydroxylamine hydrochloride (HA, 98%),

114

lysine methyl ester (LME) and n-butylamine (BL, >99.5%) were from Sigma-Aldrich.

115

Gliadin, pepsin (3800 units/mg solid), trypsin (activity 10000 BAEE units/mg) and tTG

116

from guinea pig liver (4 units/mg solid) were purchased from Sigma-Aldrich. IMDM

117

used in cell culture was obtained from Lonza (BioWhittaker®, Belgium). Other

118

chemicals were of analytical grade.

119 120

Modification of peptides by mTG and tTG



Page 6 of 35

121

In order to study the effect of pH on the transamidation and deamidation reaction, the

122

experiments were performed according to a previous study with some modifications 26.

123

In preliminary experiments, we observed that the mTG enzyme activity at pH 8.0 is

124

lower than at pH 6.0, in agreement with previous work

125

with the aim of achieving optimal transmidation at both low and high pH we choose to

126

use 0.13 U mTG at pH 8.0 and 0.50 U mTG at pH 6.0. All mTG experiments were

127

carried out in 200 mM HEPES buffer. For determination of the effect of pH on

128

transamidation 0.19 µmol 33-mer, 0.50 U mTG with either 40 µmol Lys or 40 µmol HA

129

was incubated in 1 ml buffer at either pH 6.0, 7.0 or 8.0 for 1 h. To determine the effect

130

of the acyl-acceptor concentration on the transamidation reaction 0.19 µmol 33-mer,

131

0.13 U mTG and a concentration range of GEE (0.16 µmol, 0.63 µmol, 2.50 µmol, 10

132

µmol or 40 µmol) was incubated in 1 ml of buffer at pH 6.0 for 1 h.

133

On the basis of previous work 27 and the effect of the acyl-acceptor concentration on the

134

transamidation reaction, it was deduced that the 33-mer has three modification sites,

135

whereas the DQ2.5-glia-α1a and DQ2.5-glia-α2 have one modification site. Therefore, a

136

1:210 molar ratio between the 33-mer peptide and acyl-acceptor molecule and a 1:70

137

molar ratio between DQ2.5-glia-α1a/DQ2.5-glia-α2 and acyl-acceptor molecule was

138

selected. As Lys has a pKa value that is substantially higher as that of both GEE and

139

HA 23, we choose to use pH 8.0 in case of Lys and pH 6.0 in case of HA and GEE for

140

all further experiments. In detail, 0.19 µmol 33-mer, 0.50 U mTG and 40 µmol Lys was

141

incubated in 1 ml reaction mixture at pH 8.0, while 0.19 µmol 33-mer, 0.13 U mTG and

142

40 µmol GEE/HA was incubated in 1 ml reaction mixture at pH 6.0. For DQ2.5-glia-

143

α1a and DQ2.5-glia-α2, 0.57 µmol peptide, 0.50 U mTG and 40 µmol Lys was

144

incubated in a final volume of 1 ml at pH 8.0, and 0.57 µmol peptide, 0.13 U mTG and

22

. Based on these results and


Page 7 of 35


145

40 µmol GEE, HA, LME or BL was incubated in a final volume of 1 ml at pH 6.0. For

146

deamidation 0.19 µmol of 33-mer peptide or 0.57 µmol DQ2.5-glia-α1a/α2 and 0.50 U

147

mTG were mixed in 1 ml at pH 6.0, 7.0 or 8.0.

148

The reaction mixtures were preincubated for 5 min at 50 °C before adding mTG. mTG

149

treatment was carried out at 50 °C for 1 h, followed by termination of the enzymatic

150

reaction by heating at 85-90 °C for 10 min. Subsequently, in selected experiments, tTG

151

treatment was performed by incubating 50 µl mTG-transamidated product with 15 ul

152

tTG (1 mg/ml ) in a final volume of 65 µl at 37 °C, pH 6.5 for 16 h, in 200 mM HEPES

153

buffer with 8 mM CaCl2.

154 155

Mass spectrometry

156

Mass spectrometric analysis of the synthetic gluten peptides before and after mTG and

157

tTG-mTG treatment was performed on a Bruker Microflex (MALDI TOF), and a

158

Thermo Fisher LTQ-FT Ultra.

159

For MALDI TOF part, matrix solution (10 mg/ml α-cyano-4-hydroxycinnamic acid in

160

50:50 acetonitrile/water with 0.2% TFA) was prepared. Next, peptide solutions were

161

mixed with 1 µl of matrix solution on a 96 wells target plate. Measurements were

162

detected in reflectron mode with acquisition mass range of 500-5000 Da. For DQ2.5-

163

glia-α1a, DQ2.5-glia-α2 peptides and their modified forms, measured average masses

164

were

165

(VNTPEHVVPYGLGSPSRS, monoisotopic mass 1895.96). Peptide Calibration

166

Standard from Bruker was used to calibrate the data of the 33-mer peptide and its

167

modified forms.

corrected

based

on

the

mass

of

the

reference

peptide



Page 8 of 35

168

For fourier Transform Ion Cyclotron Resonance(FT-ICR) mass spectrometry, peptides

169

were measured by tandem MS, equipped with a nanoflow liquid chromatography 1100

170

HPLC system (Agilent Technologies), as previously described 28. Peptides were trapped

171

at 10 µl/min on a 1.5 cm column (100-µm ID ReproSil-Pur C18-AQ, 3 µm, Dr. Maisch

172

GmbH, Germany) and eluted to a 20 cm column (50-µm ID; ReproSil-Pur C18-AQ, 3

173

µm) at 150 nl/min. The column was developed with a 20-min gradient from 0 to 30%

174

acetonitrile in 0.1% formic acid. The end of the nanocolumn was drawn to a tip (ID

175

about 5 µm), from which the eluent was sprayed into a LTQ-FT Ultra mass

176

spectrometer (Thermo Electron). The mass spectrometer was operated in data-

177

dependent mode, automatically switching between MS and MS/MS acquisition. Full

178

scan MS spectra were acquired in the FT-ICR with a resolution of 25,000 at a target

179

value of 3,000,000. The two most intense ions were then isolated for accurate mass

180

measurements by a selected ion monitoring scan in FT-ICR with a resolution of 50,000

181

at a target accumulation value of 50,000. The selected ions were then fragmented in the

182

linear ion trap using collision-induced dissociation at a target value of 10,000.

183

The tandem mass spectra of modified and unmodified gliadin peptides were compared

184

and manually interpreted to determine the site of modification.

185 186

Gliadin preparation and modification

187

For the purpose of modification of gliadin in solution, a pepsin/trypsin digest of gliadin

188

was prepared as described previously with some modifications

189

was solubilized in 10 ml of 1 M acetic acid and boiled for 10 min. Subsequently, 10 mg

190

of pepsin was added and the mixture was incubated for 4 h at 37°C followed by the

191

adjustment of the pH to 7.8 with NaOH and the addition of 10 mg of trypsin. Next, the

29

. First, 1g of gliadin


Page 9 of 35


192

mixture was incubated for another 4 h at 25°C. Finally, the mixture was dialysed with

193

water (molecular weight cut-off, 14 kDa), followed by concentrating using 10 kDa

194

centrifugal filter units. The protein concentration was determined by a bicinchoninic

195

acid (BCA) assay.

196

mTG treatment of the gliadin preparation was performed as follows: 1 mg of gliadin

197

was mixed with 0.50 U mTG and 10 µmol, 40 µmol or 160 µmol Lys in a final volume

198

of 1 ml at pH 8.0. For transamidation with GEE and HA, 1 mg of gliadin, 0.13 U mTG

199

and 10 µmol, 40 µmol or 160 µmol acyl-acceptor molecules were mixed in a final

200

volume of 1 ml at pH 6.0. For the mTG mediated deamidation, the reaction solution was

201

prepared using 1 mg of gliadin and 0.50 U mTG.

202

The reaction mixtures were preincubated for 5 min at 50 °C before adding mTG. mTG

203

treatment was carried out at 50 °C for 1 h, followed by termination of the enzymatic

204

reaction by heating at 85-90 °C for 10 min. Subsequently, tTG treatment was performed

205

by incubating 50 µl mTG-transamidated product with 15 ul tTG (1 mg/ml ) in a final

206

volume of 65 µl at 37 °C, pH 6.5 for 16 h, in 200 mM HEPES buffer with 8 mM CaCl2.

207 208

T-cell proliferation assays

209

Proliferation assays were performed in triplicate in 150 µl IMDM medium

210

supplemented with 2 mM glutamine and 10% human serum in 96-well flat-bottom

211

plates as previously described

212

antigen-presenting cells (105) were incubated with 50 µl antigen for 2 h, followed by the

213

addition of 15,000 DQ2.5-glia-α1 or DQ2.5-glia-α2 specific T-cell clones. All

214

conditions were carried out in triplicates. After 48 h at 37°C, 0.5 µCi of 3H-

215

thymidine/well was added to the cultures and the cells were harvested 18 h later. mTG-

30

. In brief, Irradiated (3000 rad) HLA-DQ2-matched



Page 10 of 35

216

and tTG-mTG-treated 33-mer were used at 9.48 nmol/ml, 3.16 nmol/ml, 1.05 nmol/ml,

217

0.35 nmol/ml and 0.12 nmol/ml. mTG- and tTG-mTG-treated DQ2.5-glia-α1a peptide

218

or DQ2.5-glia-α2 peptide were used at 28.43 nmol/ml, 9.48 nmol/ml, 3.16 nmol/ml,

219

1.05 nmol/ml or 0.35nmol/ml. mTG- and tTG-mTG-treated gliadin was used at 20

220

µg/ml. Both native and deamidated versions of DQ2.5-glia-α1a, DQ2.5-glia-α2 and 33-

221

mer peptides were used as controls. After 48 h at 37°C, 0.5 µCi of 3H-thymidine/well

222

was added to the cultures and the cells were harvested 18 h later. 3H-thymidine

223

incorporation in the T-cell DNA was determined with a liquid scintillation counter

224

(1205 Betaplate Liquid Scintillation Counter, USA) and results are expressed as the

225

mean counts per minute (c.p.m.).

226 227

Statistical analysis.

228

Statistical analyses were performed with GraphPad Prism 7 software. Values are

229

presented as the mean ± standard deviation (SD) (n ≥ 3).

230 231

RESULTS

232

Effect of pH and concentration of acyl-acceptor molecule on modification of gliadin

233

peptides by mTG

234

To achieve optimal modification of gliadin peptides by mTG we first determined the

235

effect of pH and the concentration of the acyl-acceptor molecule in two separate

236

experiments. To determine the effect of pH we incubated the 33-mer α-gliadin peptide,

237

known to contain three glutamine residues that can be targeted by transglutaminases,

238

with mTG and a molar excess of Lys and HA at pH 6.0, pH 7.0 or pH 8.0. The MALDI-

239

TOF analysis of the end product demonstrate that at all three pH values this resulted in


Page 11 of 35


240

shifts in molecular mass of 387 Da in the case of Lys (Figure 1A) and 48 Da in the case

241

of HA (Figure 1B), indicative of the addition of three Lys and three HA molecules

242

respectively. Moreover, the modification was highly efficient as more than 99% of the

243

33-mer peptide was modified. Similarly, incubation of the 33-mer peptide with mTG

244

and the acyl acceptor GEE also resulted in near complete modification at every pH

245

tested as demonstrated by a shift of 258 Da in the mass of the peptide, corresponding to

246

the addition of three GEE molecules (data not shown). Also, similar results were

247

obtained with both the DQ2.5-glia-α1a (Supplementary Figure 1A-C) and DQ2.5-glia-

248

α2 peptides (Supplementary Figure 1E-G). Together these results demonstrate that the

249

pH did not have a major impact on the transamidation reaction with any of the three

250

acyl-acceptor molecules.

251

To determine the effect of the concentration of the acyl-acceptor molecule on the

252

transamidation reaction, the 33-mer α-gliadin peptide was incubated with mTG in the

253

presence of 5 different concentrations of GEE. The MALDI-TOF analysis of the end

254

products demonstrate that at low concentrations of GEE (0.16 and 0.63 µmol/ml) the

255

modification was incomplete with either one, two or three additions of the acyl-acceptor

256

molecules to the gliadin peptide (Figure 1C). In contrast, at higher concentrations (2.50,

257

10 and 40 µmol/ml) more than 99% of the 33-mer was modified at three sites (Figure

258

1C). To ensure (near) complete modification of the gliadin peptides we choose to use 40

259

µmol/ml acyl-acceptor concentrations for all further experiments.

260

In contrast, the pH did influence mTG-mediated deamidation (Supplementary Figure

261

1D and 1H). In line with previous results

262

maximal at pH 6.0 and lower at neutral and basic pH.

22, 31

, the deamidation activity of mTG was



Page 12 of 35

263

Next we determined the mTG mediated modification of the DQ2.5-glia-α1a, DQ2.5-

264

glia-α2 and 33-mer peptides with three distinct acyl-acceptor molecules, Lys, GEE and

265

HA under the optimal conditions determined above. The MALDI-TOF analysis

266

indicated that the 33-mer peptide shifted 387, 258 and 48 Da upon modification with

267

Lys, GEE and HA respectively, corresponding to the addition of three Lys, GEE and

268

HA respectively (Figure 1D). Similarly, the modification of the DQ2.5-glia-α1a (Figure

269

1E) and DQ2.5-glia-α2 (Figure 1F) peptides resulted in shifts of 129, 86 and 16 Da,

270

corresponding to the addition of a single Lys, GEE and HA group. In addition, we

271

observed that both lysine methyl ester and n-butylamine could be similarly coupled to

272

gliadin by mTG (new Supplementary Figure 4 and Figure 6). In all cases the

273

modification was nearly complete as demonstrated by the disappearance of the

274

unmodified peptide and the sodium and calcium adducts thereof upon treatment with

275

mTG. Together this demonstrates that mTG can effectively catalyse the transamidation

276

reaction between all tested acyl-acceptor molecules and glutamine residues in the three

277

tested gliadin peptides.

278 279

Identification of mTG modified glutamine residues in gliadin peptides

280

In the above experiments we observed that a single acyl-acceptor molecule was coupled

281

to the

282

the 33-mer peptide, which indicates that the three tTG target glutamines in these

283

peptides are also modified by mTG. To verify that this is indeed the case the DQ2.5-

284

glia-α1a and DQ2.5-glia-α2 peptide were treated with mTG and acyl-acceptor

285

molecules and the end products were analyzed by FT-ICR. The resulting MS/MS

286

spectra of the peptides and fragments thereof indicated that over 99% of the peptides

DQ2.5-glia-α1a and DQ2.5-glia-α2 peptides while three groups were added to


Page 13 of 35


287

were transamidated with all three acyl-acceptor molecules (DQ2.5-glia-α1a: 99.7%

288

(Lys), 99.6% (GEE) and 99.5% (HA); DQ2.5-glia-α2: 99.8% (Lys), 99.6% (GEE) and

289

99.8% (HA)), confirming the results obtained with the MALDI-TOF analysis.

290

For DQ2.5-glia-α1a (Figure 2A), the MS/MS spectra obtained from the fragmentation

291

of the native and Lys-modified peptides reveal a series of b- and y-ions where the shift

292

in m/z of 936 for the b8-ion from the native peptide to 1065 in the modified peptide

293

indicates that the Lys modification occurred at the glutamine residue of p8 in the

294

peptide. This is confirmed by the observed shift in m/z from 842 to 971 for the y7-ion

295

(Figure 2A). Similar results were obtained when GEE and HA were used as acyl-

296

acceptor molecules (Supplementary Figure 2A).

297

Similarly, for the DQ2.5-glia-α2 peptide the MS/MS spectra indicate a shift in m/z from

298

808 to 937 for the b7-ion, demonstrating that the Lys modification was at the glutamine

299

at p6 in the peptide (Figure 2B). Similar results were obtained with the GEE and HA

300

modifications (Supplementary Figure 2B). Thus, mTG selectively modifies the gliadin

301

peptides at a single position which corresponds to Q8 in DQ2.5-glia-α1a and Q6 in

302

DQ2.5-glia-α2. Moreover, the transamidation was nearly complete in all cases.

303 304

Abrogation of immunogenic properties of gliadin peptides is both acyl-acceptor

305

molecule and T-cell clone dependent

306

To evaluate whether the treatment of peptides with mTG and the three acyl-acceptor

307

molecules abrogated their immune stimulatory properties, four T-cell clones specific for

308

DQ2.5-glia-α1a and four T-cell clones specific for DQ2.5-glia-α2 that have been

309

previously isolated from intestinal biopsies of patients were used. The TCR usage of all



4

Page 14 of 35

310

T-cell clones was determined previously

and each T-cell clone expressed a unique

311

TCR (Supplementary Table 1).

312

For both the DQ2.5-glia-α1a and DQ2.5-glia-α2-specific T-cell clones the Lys and GEE

313

modification of the DQ2.5-glia-α1a and DQ2.5-glia-α2 peptides virtually abrogated the

314

T-cell response while modification with HA (Figure 3A-F,) and BL (Supplementary

315

Figure 6B) was hardly effective. Similarly, Lys but not HA modification of the 33-mer

316

peptide strongly reduced the response of the T-cell clones while GEE modification was

317

less effective for T-cell clone S2 (Figure 3C). To further investigate the effectiveness of

318

the modification with the acyl-acceptor molecules, we tested two additional DQ2.5-glia-

319

α1a and two DQ2.5-glia-α2 specific T-cell clones. In line with the above observations

320

the Lys modification was found to be highly effective for the gliadin epitopes (Figure

321

3A-B and 3E-F), the 33-mer (Figure 3C-D and 3E-F) and the gliadin protein (Figure

322

3G-H) while the HA modification was hardly effective. In contrast, the GEE

323

modification was found to inhibit the response of all DQ2.5-glia-α2 specific T-cell

324

clones but proved ineffective in the case of two of the DQ2.5-glia-α1a specific T-cell

325

clones tested. Additionally, the three T-cell clones, L6, L10 and L3-13 also responded

326

significantly to the non-deamidated native gliadin peptides.

327 328

tTG-catalyzed hydrolysis of transamidated products can generate deamidated T-cell

329

epitopes

330

Upon ingestion of mTG transamidated gliadin it could come into contact with intestinal

331

tTG. To determine the potential effect of this on the immune stimulatory properties of

332

the mTG treated gliadin we treated mTG transamidated DQ2.5-glia-α1a, DQ2.5-glia-α2

333

and 33-mer with tTG and determined the effect through mass spectrometry. After


Page 15 of 35


334

incubation with tTG a proportion of the Lys-modified peptide was found to be

335

delysinated, resulting in deamidated gliadin (Figure 4A-C). Simultaneously, LME- and

336

BL-modified peptide also partially was reversed by tTG (Supplementary Figure 4 and

337

Supplementary Figure 6). Moreover, T-cell clones specific for the DQ2.5-glia-α1a

338

(Figure 5A-B), and DQ2.5-glia-α2 (Figure 5C-D and Supplementary Figure 6B),

339

epitopes responded to the tTG treated samples compared to the control and mTG treated

340

samples, indicating that tTG had indeed reversed the transamidation of a proportion of

341

the mTG treated epitopes. Similarly, we observed that tTG can partially reverse the

342

mTG-mediated transamidation of gliadin protein (Figure 5E-F).

343 344

DISCUSSION

345

Wheat-based products are one of the most commonly consumed foods worldwide. As

346

wheat gluten is the causative agent in celiac disease, this implies that a large number of

347

food products are off limit for patients suffering from this condition. While the

348

availability of bona fide gluten-free products has increased significantly in recent years,

349

these are not always a good replacement for gluten-containing foods due to the special

350

properties of gluten proteins that confer superior baking properties to wheat based-

351

products 32. Also, an inappropriate gluten-free diet can cause nutritional shortcomings,

352

often lacks sufficient fiber

353

gluten proteins would be one approach to overcome such shortcomings. The molecular

354

basis for the toxic properties of gluten is well established as T-cells specific for

355

modified gluten fragments bound to the disease-predisposing HLA-DQ2 and -DQ8

356

molecules reside in the intestine of patients 1. Upon activation such T-cell secrete pro-

357

inflammatory cytokines leading to inflammation and remodelling of the intestinal

33

and persists reduced digestibility

34

. Detoxification of



Page 16 of 35

358

morphology. The modification of gluten is an enzymatic conversion of particular

359

glutamine residues in gluten fragments into glutamic acid, introducing a negative charge

360

that allows high-affinity binding to either HLA-DQ2 or -DQ8. The enzyme involved,

361

tTG, specifically modifies glutamine residues in QXP sequences (where X can be any

362

amino acid except proline), but not in QP sequences, which results in highly selective

363

modification of particular glutamine residues only due to the proline-rich nature of

364

gluten proteins

365

been proposed as an approach to prohibit the conversion of glutamine to glutamic acid

366

by tTG. Indeed, enzymatic coupling of Lys to the tTG target glutamines in gluten has

367

been shown to diminish the immunogenicity of gluten

368

been shown to effectively mediate this transamidation

369

analysis of the effectiveness of such an approach with a panel of well characterized

370

gluten-specific T-cell clones from patients is currently lacking. Moreover, the coupling

371

of the relatively large amino acid Lys to several glutamine residues in gluten proteins

372

may affect their unique properties. Therefore, in the present study we have determined

373

if smaller acyl-acceptor molecule would be equally capable of reducing the

374

immunogenic properties of gluten proteins and peptides. Our results provide detailed

375

insight into the transamidation of gliadin peptides and proteins by mTG and three

376

distinct acyl-acceptor molecules. We have used mass spectrometry to determine the

377

extent and exact location of the mTG mediated modifications and we have exploited the

378

availability of gliadin-specific T-cell clones to monitor the impact of these

379

modifications in detail. Finally, we have investigated if tTG could revert the effect of

380

mTG-mediated transamidation.

381

Our results demonstrate that the DQ2.5-glia-α1a, DQ2.5-glia-α2 and 33-mer peptides

11, 27

. Enzymatic modification of these glutamine residues has therefore

16

. In addition, mTG has also 16

. However, a systematic


Page 17 of 35


382

were almost completely transamidated by mTG with all five acyl-acceptor molecules

383

used, which confirms and extends the previous observation that mTG has a strong

384

transamidation activity

385

impact on the transamidation reaction, indicating that transamidation of gluten proteins

386

by mTG would be robust under a variety of conditions. However, in agreement with

387

previous observations 22 mTG displayed pH-dependent deamidation activity which was

388

maximal at pH 6.0 and minimal at pH 8.0. Thus, mTG mediated modification of gluten

389

should preferably be carried out at higher pH values to avoid the deamidation of gluten

390

which is known to increase immunogenicity. Importantly, our results indicated that

391

mTG targeted the same glutamine residues that are modified by tTG in both the DQ2.5-

392

glia-α1a, DQ2.5-glia-α2 and in the 33-mer gliadin peptide (Figure 2 and Supplementary

393

Figure 2). Thus, the transamidation of gluten by mTG can be used to prevent the

394

deamidation of gluten which enhances the binding of gluten epitopes to HLA-DQ

395

molecules. Our results are in contrast to a recent study 22 where two glutamine residues

396

were transamidated in the peptide QPFPQPQLPYPQPQ, encompassing both the

397

DQ2.5-glia-α1a and DQ2.5-glia-α2 epitopes. This may be due to different reaction

398

conditions such as the concentration of acyl-acceptor molecules and reaction time

399

employed.

400

We have used a panel of well characterized T-cell clones to evaluate the effect of the

401

transamidation of gliadin peptides and proteins. While it is likely that abrogation of T-

402

cell reactivity against transamidated gliadin peptides results from impaired binding to

403

HLA-DQ, transamidation may also affect the conformation of the gliadin peptide in

404

HLA-DQ, a possibility that cannot be inferred from the results with the T-cells.

405

Nonetheless, whatever the mechanism, abrogation of T-cell stimulatory properties

22

. Similarly, we observed that the pH did not have a major



Page 18 of 35

406

would gluten render safe for consumption by celiac disease patients.

407

While the transamidation of the Q residues in the DQ2.5-glia-α1a and DQ2.5-glia-α2

408

epitopes was nearly complete with all three acyl-acceptor molecules, significant

409

differences were found with respect to the response of T-cell clones specific for these

410

epitopes. In agreement with previous results

411

reduced the proliferation of all T-cell clones. In contrast, the modification with GEE

412

was similarly effective in case of DQ2.5-glia-α2-specific T-cell clones but less effective

413

for DQ2.5-glia-α1-specific T-cell clones. This may relate to the featureless central

414

region of the DQ2.5-glia-α1a peptide while bound to HLA-DQ2.5 4 where the relatively

415

small addition of the GEE group may not affect the binding interface with the T-cell

416

receptor. Strikingly, the modification with HA was largely ineffective even though this

417

acyl-acceptor molecule was coupled as efficiently as the Lys and GEE groups.

418

Presumably, the HA-modification had little effect on the binding of the modified

419

peptides while that with GEE and Lys does. In this respect it is important to note that

420

several of the T-cell clones also responded significantly to the non-deamidated native

421

gliadin peptides, in line with previous results indicating that deamidation of gluten

422

peptides is not always a prerequisite for T-cell recognition 29, 30. As such, transamidation

423

of gliadin would not only prevent deamidation but would also eliminate T-cell

424

responses to native gliadin peptides. Importantly, mTG-transamidation of gliadin also

425

abolished the T-cell stimulatory properties. However, as not all T-cell clones tested

426

were equally affected by the mTG mediated transamidation, this may imply that the

427

effect of mTG mediated transamidation can vary from patient to patient depending on

428

the expressed T-cell receptor repertoire.

429

Finally, we demonstrate that guinea pig derived tTG can partially undo the mTG

16

, the modification with Lys drastically


Page 19 of 35


430

mediated transamidation reaction as we observed T-cell responses to mTG-

431

transamidated gliadin peptides that were subsequently treated with tTG, a result

432

consistent with a previous observation that tTG can hydrolyze iso-peptide bonds

433

While evidence for hydrolysation of the iso-peptide bond was already apparent after 1

434

h, it is of note that most of the transamidated peptide was still intact even after 16 h

435

incubation. Moreover, it is unclear whether human tTG can hydrolyze iso-peptide bonds

436

as this is distinct from guinea pig tTG which could affect catalytic activity and substrate

437

specificity

438

mediated transamidation with other approaches to reduce the immunogenicity of gluten

439

38, 39

440

In conclusion, our results confirm previous results that mTG can effectively

441

transamidate gliadin peptides and gluten proteins. We demonstrate that transamidation

442

with Lys is most effective to abrogate the immune stimulatory properties of gluten

443

while the coupling of smaller acyl-acceptor molecule is less (GEE) effective or mostly

444

ineffective (HA). At present transamidation with lysine is thus the only available option

445

to eliminate gluten toxicity. In this respect it is important to note that food grade lysine

446

is readily available on the market, potentially enabling the large scale production of

447

transamidated gluten for incorpotation in food products. However, our results on the

448

reversibility of the mTG mediated transamidation indicate that this may also occur in

449

vivo. Thus, additional studies are required to test the impact of these modifications on

450

gluten baking properties and in vivo antigenicity to evaluate the general applicability of

451

this approach in practice.

35

.

36, 37

. Finally, in future studies it may be worthwhile to combine mTG

.

452 453

ABBREVIATIONS



Page 20 of 35

454

APC, antigen-presenting cell; CD, celiac disease; FT-ICR, fourier transform ion

455

cyclotron resonance; GEE, glycine ethyl ester; glia, gliadin; HA, hydroxylamine; Lys,

456

L-lysine; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight;

457

mTG, microbial transglutaminase; TCR, T-cell receptor; tTG, tissue transglutaminase.

458 459

ACKNOWLEDGMENT

460

We thank Cees Franken for help with the gliadin preparation. L.Z. was supported by

461

Nanchang University.

462 463

SUPPORTING INFORMATION

464

Supplementary Table 1. HLA-DQ2.5-glia-α1/α2-specificT-cell clones and their TCR gene

465

usage

466

Supplementary Figure 1. Effect of pH on transamidation and deamidation of DQ 2.5-

467

glia-α1a and DQ 2.5-glia-α2 peptides

468

Supplementary Figure 2. Identification of transamidated sites induced by mTG using

469

LTQ-FT Ultra

470

Supplementary Figure 3. Identification of tTG-mediated deamidation of transamidated DQ2.5-

471

glia-α2 by MALDI-TOF.

472

Supplementary Figure 4. Transamidation of DQ2.5-glia-α2 with LME and effect of

473

tTG treatment of transamidated peptide.

474

Supplementary Figure 5. Time-tracking of mTG transamidation by MALDI-TOF.

475

Supplementary Figure 6. Transamidation of DQ2.5-glia-α2 with BL and reactivity pattern

476

of glia-α2-specific-T-cell clone to mTG-treated and tTG-mTG treated peptide.

477


Page 21 of 35


478

5 REFERENCES

479

(1) Di Sabatino, A.; Corazza, G. R. Coeliac disease. Lancet 2009, 373, 1480-1493.

480

(2) Karell, K.; Louka, A. S.; Moodie, S. J.; Ascher, H.; Clot, F.; Greco, L.; Ciclitira, P.

481

J.; Sollid, L. M.; Partanen, J.; Disease, E. G. C. o. C. HLA types in celiac disease

482

patients not carrying the DQA1* 05-DQB1* 02 (DQ2) heterodimer: results from the

483

European Genetics Cluster on Celiac Disease. Hum. Immunol. 2003, 64, 469-477.

484

(3) Petersen, J.; Kooy-Winkelaar, Y.; Loh, K. L.; Tran, M.; Van Bergen, J.; Koning, F.;

485

Rossjohn, J.; Reid, H. H. Diverse T Cell Receptor Gene Usage in HLA-DQ8-

486

Associated Celiac Disease Converges into a Consensus Binding Solution. Structure

487

2016, 24, 1643-1657.

488

(4) Petersen, J.; Montserrat, V.; Mujico, J. R.; Loh, K. L.; Beringer, D. X.; Van

489

Lummel, M.; Thompson, A.; Mearin, M. L.; Schweizer, J.; Kooy-Winkelaar, Y. T-cell

490

receptor recognition of HLA-DQ2-gliadin complexes associated with celiac disease.

491

Nat. Struct. Mol. Biol. 2014, 21, 480-488.

492

(5) Sollid, L. M.; Qiao, S.-W.; Anderson, R. P.; Gianfrani, C.; Koning, F.

493

Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by

494

HLA-DQ molecules. Immunogenetics 2012, 64, 455-460.

495

(6) Qiao, S.-W.; Bergseng, E.; Molberg, Ø.; Xia, J.; Fleckenstein, B.; Khosla, C.;

496

Sollid, L. M. Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin

497

peptide naturally formed by gastrointestinal digestion. J. Immunol. 2004, 173, 1757-

498

1762.

499

(7) Shan, L.; Molberg, Ø.; Parrot, I.; Hausch, F.; Filiz, F.; Gray, G. M.; Sollid, L. M.;

500

Khosla, C. Structural basis for gluten intolerance in celiac sprue. Science 2002, 297,

501

2275-2279.



Page 22 of 35

502

(8) Anderson, R. P.; Degano, P.; Godkin, A. J.; Jewell, D. P.; Hill, A. V. In vivo

503

antigen challenge in celiac disease identifies a single transglutaminase-modified peptide

504

as the dominant A-gliadin T-cell epitope. Nat. Med. 2000, 6, 337-342.

505

(9) Arentz-Hansen, H.; Körner, R.; Molberg, Ø.; Quarsten, H.; Vader, W.; Kooy, Y.

506

M.; Lundin, K. E.; Koning, F.; Roepstorff, P.; Sollid, L. M. The intestinal T cell

507

response to α-gliadin in adult celiac disease is focused on a single deamidated glutamine

508

targeted by tissue transglutaminase. J. Exp. Med. 2000, 191, 603-612.

509

(10) Molberg, Ø.; McAdam, S.; Lundin, K. E.; Kristiansen, C.; Arentz‐Hansen, H.;

510

Kett, K.; Sollid, L. M. T cells from celiac disease lesions recognize gliadin epitopes

511

deamidated in situ by endogenous tissue transglutaminase. Eur. J. Immunol. 2001, 31,

512

1317-1323.

513

(11) Dekking, E.; Van Veelen, P.; De Ru, A.; Kooy-Winkelaar, E.; Gröneveld, T.;

514

Nieuwenhuizen, W.; Koning, F. Microbial transglutaminases generate T cell stimulatory

515

epitopes involved in celiac disease. J. Cereal Sci. 2008, 47, 339-346.

516

(12) Kristiansen, C.; Madsen, L.; Fugger, L.; Scott, H.; Norén, O.; Roepstorff, P.;

517

Lundin, K. E.; Sjöström, H.; Sollid, L. M. Tissue transglutaminase selectively modifies

518

gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med.

519

1998, 4, 713-7.

520

(13) van de Wal, Y.; Kooy, Y.; van Veelen, P.; Peña, S.; Mearin, L.; Papadopoulos, G.;

521

Koning, F. Cutting edge: selective deamidation by tissue transglutaminase strongly

522

enhances gliadin-specific T cell reactivity. J. Immunol. 1998, 161, 1585-1588.

523

(14) Cabrera-Chávez, F.; Rouzaud-Sández, O.; Sotelo-Cruz, N.; Calderón de la Barca,

524

A. M. Transglutaminase treatment of wheat and maize prolamins of bread increases the


Page 23 of 35


525

serum IgA reactivity of celiac disease patients. J. Agric. Food Chem. 2008, 56, 1387-

526

1391.

527

(15) Ruh, T.; Ohsam, J. r.; Pasternack, R.; Yokoyama, K.; Kumazawa, Y.; Hils, M.

528

Microbial transglutaminase treatment in pasta-production does not affect the

529

immunoreactivity of gliadin with celiac disease patients’ sera. J. Agric. Food Chem.

530

2014, 62, 7604-7611.

531

(16) Gianfrani, C.; Siciliano, R. A.; Facchiano, A. M.; Camarca, A.; Mazzeo, M. F.;

532

Costantini, S.; Salvati, V. M.; Maurano, F.; Mazzarella, G.; Iaquinto, G. Transamidation

533

of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease.

534

Gastroenterology 2007, 133, 780-789.

535

(17) Lombardi, E.; Bergamo, P.; Maurano, F.; Bozzella, G.; Luongo, D.; Mazzarella,

536

G.; Aufiero, V. R.; Iaquinto, G.; Rossi, M. Selective inhibition of the gliadin-specific,

537

cell-mediated immune response by transamidation with microbial transglutaminase. J.

538

Leukocyte Biol. 2013, 93, 479-488.

539

(18) Elli, L.; Roncoroni, L.; Hils, M.; Pasternack, R.; Barisani, D.; Terrani, C.; Vaira,

540

V.; Ferrero, S.; Bardella, M. T. Immunological effects of transglutaminase-treated

541

gluten in coeliac disease. Hum. Immunol. 2012, 73, 992-997.

542

(19) Mazzarella, G.; Salvati, V. M.; Iaquinto, G.; Stefanile, R.; Capobianco, F.;

543

Luongo, D.; Bergamo, P.; Maurano, F.; Giardullo, N.; Malamisura, B. Reintroduction

544

of gluten following flour transamidation in adult celiac patients: a randomized,

545

controlled clinical study. Clin. Dev. Immunol. 2012, 2012, 329150.

546

(20) Heredia-Sandoval, N. G.; Islas-Rubio, A. R.; Cabrera-Chávez, F.; de la Barca, A.

547

M. C. Transamidation of gluten proteins during the bread-making process of wheat



Page 24 of 35

548

flour to produce breads with less immunoreactive gluten. Food Funct. 2014, 5, 1813-

549

1818.

550

(21) Ribeiro, M.; Nunes, F. M.; Guedes, S.; Domingues, P.; Silva, A. M.; Carrillo, J.

551

M.; Rodriguez-Quijano, M.; Branlard, G.; Igrejas, G. Efficient chemo-enzymatic gluten

552

detoxification: reducing toxic epitopes for celiac patients improving functional

553

properties. Sci. Rep. 2015, 5, 18041.

554

(22) Heil, A.; Ohsam, J.; Büchold, C.; Pasternack, R.; Yokoyama, K.; Kumazawa, Y.;

555

Hils, M. Microbial transglutaminase has a lower deamidation preference than human

556

tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope. J.

557

Cereal Sci. 2016, 70, 47-56.

558

(23) Gundersen, M. T.; Keillor, J. W.; Pelletier, J. N. Microbial transglutaminase

559

displays broad acyl-acceptor substrate specificity. Appl. Microbiol. Biotechnol. 2014, 98,

560

219-230.

561

(24) Ohtsuka, T.; Sawa, A.; Kawabata, R.; Nio, N.; Motoki, M. Substrate specificities

562

of microbial transglutaminase for primary amines. J. Agric. Food Chem. 2000, 48,

563

6230-6233.

564

(25) Grossmann, I.; Döring, C.; Jekle, M.; Becker, T.; Koehler, P. Compositional

565

changes and baking performance of rye dough as affected by microbial

566

transglutaminase and xylanase. J. Agric. Food Chem. 2016, 64, 5751-5758.

567

(26) Zhou, L.; Wu, Y.; Cheng, Y.; Wang, J.; Lu, J.; Gao, J.; Yuan, J.; Chen, H.

568

Blocking celiac antigenicity of the glutamine-rich gliadin 33-mer peptide by microbial

569

transglutaminase. RSC Adv. 2017, 7, 14438-14447.

570

(27) Vader, L. W.; de Ru, A.; van der Wal, Y.; Kooy, Y. M.; Benckhuijsen, W.;

571

Mearin, M. L.; Drijfhout, J. W.; van Veelen, P.; Koning, F. Specificity of tissue


Page 25 of 35


572

transglutaminase explains cereal toxicity in celiac disease. J. Exp. Med. 2002, 195, 643-

573

649.

574

(28) Meiring, H.; Van der Heeft, E.; Ten Hove, G.; De Jong, A. Nanoscale LC-MS (n):

575

technical design and applications to peptide and protein analysis. J. Sep. Sci. 2002, 25,

576

557-568.

577

(29) Van De Wal, Y.; Kooy, Y. M.; Van Veelen, P. A.; Peña, S. A.; Mearin, L. M.;

578

Molberg, Ø.; Lundin, K. E.; Sollid, L. M.; Mutis, T.; Benckhuijsen, W. E. Small

579

intestinal T cells of celiac disease patients recognize a natural pepsin fragment of

580

gliadin. Proc. Natl. Acad. Sci. 1998, 95, 10050-10054.

581

(30) Vader, W.; Kooy, Y.; van Veelen, P.; de Ru, A.; Harris, D.; Benckhuijsen, W.;

582

Peña, S.; Mearin, L.; Drijfhout, J. W.; Koning, F. The gluten response in children with

583

celiac

584

Gastroenterology 2002, 122, 1729-1737.

disease

is

directed

toward

multiple

gliadin

and

glutenin

peptides.

585

(31) Ho, M. L.; Leu, S. Z.; Hsieh, J. F.; Jiang, S. T. Technical approach to simplify the

586

purification method and characterization of microbial transglutaminase produced from

587

Streptoverticillium ladakanum. J. Food Sci. 2000, 65, 76-80.

588 589 590 591

(32) Pellegrini, N.; Agostoni, C. Nutritional aspects of gluten-free products. J. Sci. Food Agric. 2015, 95, 2380-2385. (33) Theethira, T. G.; Dennis, M.; Leffler, D. A. Nutritional consequences of celiac disease and the gluten-free diet. Expert Rev. Gastroenterol. Hepatol. 2014, 8, 123-129.

592

(34) Gulati, P.; Li, A.; Holding, D.; Santra, D.; Zhang, Y.; Rose, D. J. Heating

593

Reduces Proso Millet Protein Digestibility via Formation of Hydrophobic Aggregates. J.

594

Agric. Food Chem. 2017, 65, 1952-1959.



Page 26 of 35

595

(35) Stamnaes, J.; Fleckenstein, B.; Sollid, L. M. The propensity for deamidation and

596

transamidation of peptides by transglutaminase 2 is dependent on substrate affinity and

597

reaction conditions. Biochim. Biophys. Acta 2008, 1784, 1804-1811.

598

(36) Roy, I.; Smith, O.; Clouthier, C. M.; Keillor, J. W. Expression, purification and

599

kinetic characterisation of human tissue transglutaminase. Protein Expression Purif.

600

2013, 87, 41-46.

601

(37) Heil, A.; Weber, J.; Büchold, C.; Pasternack, R.; Hils, M. Differences in the

602

inhibition of coagulation factor XIII-A from animal species revealed by Michael

603

Acceptor–and thioimidazol based blockers. Thromb. Res. 2013, 131, e214-e222.

604

(38) Pérot, M.; Lupi, R.; Guyot, S.; Delayre-Orthez, C.; Gadonna-Widehem, P.;

605

Thébaudin, J.-Y.; Bodinier, M.; Larré, C. Polyphenol Interactions Mitigate the

606

Immunogenicity and Allergenicity of Gliadins. J. Agric. Food Chem. 2017, 6b05371.

607

(39) Berti, C.; Roncoroni, L.; Falini, M. L.; Caramanico, R.; Dolfini, E.; Bardella, M.

608

T.; Elli, L.; Terrani, C.; Forlani, F. Celiac-related properties of chemically and

609

enzymatically modified gluten proteins. J. Agric. Food Chem. 2007, 55, 2482-2488.

610 611

FIGURE CAPTIONS

612

Figure 1. Transamidation pattern of DQ2.5-glia-α1a, DQ2.5-glia-α2 and 33-mer

613

peptide after modification using mTG and three different acyl-acceptor molecules. (A)

614

Effect of pH on 33-mer reaction induced by mTG in presence of Lys. (B) Effect of pH

615

on 33-mer reaction induced by mTG in presence of HA. (C) Effect of GEE

616

concentration on 33-mer transamidation induced by mTG at pH 6.0. Molar ratio

617

between the 33-mer peptide and GEE is 1:0.84, 1:3.32, 1:13.16, 1:52.63, 1:210.53 as

618

shown. (D) Transamidation pattern of 33-mer by mTG. As compared with native


Page 27 of 35


619

peptide, 33-mer crosslinked to Lys, GEE and HA resulted in a shift of 129 x 3 Da, 86 x

620

3 Da and 16 x 3 Da, corresponding to the addition of three Lys, GEE and HA groups

621

respectively. (E) Transamidation pattern of DQ2.5-glia-α1a by mTG. DQ2.5-glia-α1a

622

presented 129 Da, 86 Da and 16 Da shift responding to the addition of a single Lys,

623

GEE and HA group. (F) Transamidation pattern of DQ2.5-glia-α2 by mTG. DQ2.5-glia-

624

α2 presented 129 Da, 86 Da and 16 Da shift responding to the addition of a single Lys,

625

GEE and HA group. Monoisotopic mass are shown throughout.

626 627

Figure 2. Identification of transamidated sites induced by mTG using LTQ-FT Ultra.

628

(A) Observed fragment of DQ2.5-glia-α1a before treatment (upper spectrum) and after

629

treatment with mTG in presence of Lys (lower spectrum); predicted fragment ion

630

masses are given in the table with identified ions illustrating transamidation shown in

631

boxes. (B) Observed fragment of DQ2.5-glia-α2 before treatment (upper spectrum) and

632

after treatment with mTG in presence of Lys (lower spectrum); predicted fragment ion

633

masses are given in the table with identified ions illustrating transamidation shown in

634

boxes. Arrows indicate the shift in Da due to transamidation.

635 636

Figure 3. Reactivity pattern of glia-α1and glia-α2-specific-T-cell clones to DQ2.5-glia-

637

α1a, DQ2.5-glia-α2, 33-mer, gliadin and their mTG-treated forms. (A) Reactivity

638

pattern of glia-α1-specific T-cell clone S2 and L5107 to DQ2.5-glia-α1a and its

639

modified products (5 concentrations tested in each group). (B) Reactivity pattern of

640

glia-α2-specific T-cell clones S16 and D1 to DQ2.5-glia-α2 and its modified products (5

641

concentrations tested with S16 and only the highest concentration with D1). (C)

642

Reactivity pattern of glia-α1-specific T-cell clones S2 and L5107 to 33-mer and its



Page 28 of 35

643

modified products (5 concentrations tested in each group). (D) Reactivity pattern of

644

glia-α2-specific T-cell clones S16 and D1 to 33-mer and its modified products (5

645

concentrations tested with S16 and only the highest concenration with D1). (E)

646

Reactivity pattern of glia-α1-specific T-cell clones L6 and L10 to DQ2.5-glia-α1a and

647

its modified products (only the highest concenration tested). (F) Reactivity pattern of

648

glia-α2-specific T-cell clones 101136 and L3-13 to DQ2.5-glia-α2 and its modified

649

products (only the highest concenration tested). (G) Reactivity pattern of glia-α1-

650

specific T-cell clones to gliadin protein and its modified products (only the highest

651

concentration tested). (H) Reactivity pattern of glia-α2-specific T-cell clones to gliadin

652

protein and its modified products(only the highest concentration tested). PC:

653

deamidated peptides as positive control; NC: native peptides as negative control.

654

Relative response: CPM of T cell clone caused by peptide/that of caused by deamidated

655

peptide (positive control).

656 657

Figure 4. Analysis of DQ2.5-glia-α1a and DQ2.5-glia-α2 after mTG and tTG treatment

658

by MALDI-TOF. (A) Mass spectrum of DQ2.5-glia-α1a (upper panel), DQ2.5-glia-α1a

659

after mTG transamidation with Lys (mTG-Lys, middle panel), and after tTG treatment

660

of Lys transamidated DQ2.5-glia-α1a (tTG-mTG-Lys, lower panel). (B) Mass spectrum

661

of DQ2.5-glia-α2 (upper panel), DQ2.5-glia-α2 after mTG transamidation with Lys

662

(mTG-Lys, middle panel), and after tTG treatment of Lys transamidated DQ2.5-glia-α2

663

(tTG-mTG-Lys, lower panel). (C) Mass spectrum of 33-mer (upper panel), 33-mer

664

after mTG transamidation with Lys (mTG-Lys, middle panel), and after tTG treatment

665

of Lys transamidated 33-mer (tTG-mTG-Lys, lower panel). The deamidation of Q→E


Page 29 of 35


666

would be result in a 1 Da shift. Monoisotopic mass are shown throughout. Arrows

667

indicate the shift in Da after modification.

668 669

Figure 5. tTG can revert mTG-mediated transamidation. (A) Reactivity pattern of glia-

670

α1-specific T-cell clone L5107 to DQ2.5-glia-α1a (left panel), the 33-mer (right panel)

671

before (NC) and after mTG transamidation with Lys (mTG-Lys) and after tTG

672

treatment of mTG-Lys (tTG-mTG-Lys). (B) Reactivity pattern of glia-α1-specific T-cell

673

clones S2 and L6 to DQ2.5-glia-α1a, 33-mer and their modified products. (C)

674

Reactivity pattern of glia-α2-specific T-cell clone S16 to DQ2.5-glia-α2 (left panel), the

675

33-mer (right panel) before (NC) and after mTG transamidation with Lys (mTG-Lys)

676

and after tTG treatment of mTG-Lys (tTG-mTG-Lys). (D) Reactivity pattern of glia-

677

α2-specific T-cell clones D1 and 101136 to DQ2.5-glia-α2, 33-mer and their modified

678

products. (E) Reactivity pattern of glia-α1-specific T-cell clones to gliadin protein

679

before (NC) and after mTG transamidation with Lys (mTG-Lys) and after tTG

680

treatment of mTG-Lys (tTG-mTG-Lys). Three different concentrations of Lysine were

681

used, 10, 40 and 160 mM as indicated. (F) Reactivity pattern of glia-α2-specific T-cell

682

clones to gliadin protein and its modified products.

683 684 685 686 687 688 689



Page 30 of 35

FIGURES

Figure 1.


Page 31 of 35


Figure 2.



Page 32 of 35

Figure 3.


Page 33 of 35


Figure 4.



Page 34 of 35

Figure 5.


Page 35 of 35


Gliadin H2N Lys O C N H2 + H2N GEE H2N HA

Proliferation

+

4

CD

CD

4+

Acyl-donor Acyl-acceptor

TCR

mTG

+

APC

4

O C N H Lys O C N H GEE O C N H HA

4+

CD

NH3

CD

HLA-DQ2

ACS Paragon Plus Environment

Abrogation of Immunogenic Properties of Gliadin Peptides through

Recommend Documents